| Autor: |
de With, Mirjam, Knikman, Jonathan, Schellens, Jan H. M., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk‐Jan, Mathijssen, Ron H. J., Swen, Jesse J., Meulendijks, Didier |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology & Therapeutics; Mar2023, Vol. 113 Issue 3, p473-475, 3p |
| Abstrakt: |
Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters" (b) Comparison of uracil concentration between patients experiencing no severe toxicity (grade 0-2) and patients who did experience severe toxicity (grade 3-5) excluding the six hospitals with the highest median uracil concentrations. We thank Thomas I et al i . for the comments on our publication[1] and continued discussion regarding the feasibility and clinical validity of plasma uracil concentration as a marker for DPD deficiency. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text